MX2019012431A - Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. - Google Patents

Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Info

Publication number
MX2019012431A
MX2019012431A MX2019012431A MX2019012431A MX2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A
Authority
MX
Mexico
Prior art keywords
ahr inhibitors
indole
inhibitors
indole ahr
ahr
Prior art date
Application number
MX2019012431A
Other languages
English (en)
Inventor
Alfredo C Castro
Catherine Anne Evans
Original Assignee
Ikena Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikena Oncology Inc filed Critical Ikena Oncology Inc
Publication of MX2019012431A publication Critical patent/MX2019012431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona compuestos útiles como inhibidores de AHR, composiciones de los mismos y métodos para usar los mismos.
MX2019012431A 2017-04-21 2018-04-20 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. MX2019012431A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762488476P 2017-04-21 2017-04-21
US201762592542P 2017-11-30 2017-11-30
US201862658454P 2018-04-16 2018-04-16
PCT/US2018/028532 WO2018195397A2 (en) 2017-04-21 2018-04-20 Indole ahr inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019012431A true MX2019012431A (es) 2020-08-03

Family

ID=63856153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012431A MX2019012431A (es) 2017-04-21 2018-04-20 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Country Status (15)

Country Link
US (4) US10570138B2 (es)
EP (1) EP3612030A4 (es)
JP (2) JP7232244B2 (es)
KR (1) KR20190141722A (es)
CN (1) CN110831600B (es)
AU (1) AU2018256459B2 (es)
BR (1) BR112019021992A2 (es)
CA (1) CA3059939A1 (es)
CL (1) CL2019003015A1 (es)
CO (1) CO2019011584A2 (es)
IL (1) IL270025B2 (es)
MX (1) MX2019012431A (es)
SG (1) SG11201909710XA (es)
TW (1) TWI778050B (es)
WO (1) WO2018195397A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP4086256A1 (en) 2016-12-16 2022-11-09 Janssen Pharmaceutica NV Small molecule inhibitors of the jak family of kinases
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
FR3066761B1 (fr) * 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
US11530220B2 (en) 2018-02-06 2022-12-20 Ideaya Biosciences, Inc. Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
FI3749669T3 (fi) 2018-02-06 2023-05-26 Ideaya Biosciences Inc AHR-modulaattoreita
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
AU2019335968B2 (en) 2018-09-07 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
AU2019360204A1 (en) * 2018-10-16 2021-06-03 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
AU2019359883A1 (en) * 2018-10-17 2021-05-20 Magenta Therapeutics Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
CA3119426A1 (en) * 2018-11-30 2020-06-04 Celularity Inc. Aromatic compounds for use in activating hematopoietic stem and progenitor cells
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
JP2022522328A (ja) * 2019-02-27 2022-04-18 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
US20220281824A1 (en) * 2019-07-30 2022-09-08 Oregon State University Aryl hydrocarbon receptor activators
AU2020386967A1 (en) * 2019-11-22 2022-07-07 Senda Biosciences, Inc. Pyridopyrimidinone derivatives as AHR antagonists
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
US20230026232A1 (en) 2019-11-26 2023-01-26 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
AR120540A1 (es) * 2019-11-26 2022-02-23 Hoffmann La Roche Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CN115190799A (zh) 2020-01-10 2022-10-14 医肯纳肿瘤学公司 Ahr抑制剂及其用途
AU2021226411A1 (en) 2020-02-26 2022-09-22 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of AhR signalling
KR20230005844A (ko) * 2020-03-27 2023-01-10 동아에스티 주식회사 아미노피리미딘 유도체 및 이의 아릴 탄화수소 수용체 조절제로서의 용도
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2022029063A1 (en) * 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
EP4236960A1 (en) 2020-10-28 2023-09-06 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
CN114644627A (zh) * 2020-12-18 2022-06-21 山东轩竹医药科技有限公司 AhR抑制剂及其用途
CN112656789A (zh) * 2020-12-31 2021-04-16 中国科学院生态环境研究中心 Ficz在抑制肿瘤细胞迁移中的应用
CN114805361B (zh) * 2021-01-17 2024-02-20 上海凌达生物医药有限公司 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
WO2023033740A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN115925684A (zh) * 2021-12-03 2023-04-07 徐诺药业(南京)有限公司 一种嘧啶类衍生物及其制备方法和应用
WO2023135057A1 (en) 2022-01-11 2023-07-20 Deutsches Krebsforschungszentrum Bicyclic triazine derivatives for the treatment of cancer
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN115804776A (zh) * 2022-12-16 2023-03-17 国纳之星(上海)纳米科技发展有限公司 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用
CN116482278B (zh) * 2023-05-06 2024-02-09 广州清瑞生物科技有限责任公司 一种用于检测阿昔洛韦的对照品的制备方法
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2003024441A1 (fr) * 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Nouvelle utilisation de composes tricycliques
US20040063730A1 (en) 2000-12-19 2004-04-01 Hans-Michael Eggenweiler Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives
KR20050058507A (ko) * 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
AU2003295332B2 (en) * 2002-09-19 2007-01-18 Merck Sharp & Dohme Corp. Imidazopyridines as cyclin dependent kinase inhibitors
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP2008520749A (ja) * 2004-11-23 2008-06-19 レディ ユーエス セラピューティックス， インコーポレイテッド 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2086979B1 (en) 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
CN101952283B (zh) * 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
KR20170119746A (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
HUE026201T2 (en) 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
ES2820517T3 (es) 2010-05-04 2021-04-21 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
NZ607710A (en) 2010-09-09 2014-11-28 Pfizer 4-1bb binding molecules
US8957077B2 (en) * 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
BR122021026173B1 (pt) 2010-12-09 2023-12-05 The Trustees Of The University Of Pennsylvania Composição farmacêutica
NO2694640T3 (es) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
KR20200011616A (ko) 2012-05-11 2020-02-03 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
AU2018253115B2 (en) 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Also Published As

Publication number Publication date
JP7232244B2 (ja) 2023-03-08
TW201841917A (zh) 2018-12-01
AU2018256459A1 (en) 2019-11-07
BR112019021992A2 (pt) 2020-06-09
WO2018195397A3 (en) 2018-12-13
US10689388B1 (en) 2020-06-23
EP3612030A4 (en) 2021-04-28
TWI778050B (zh) 2022-09-21
JP2022116319A (ja) 2022-08-09
EP3612030A2 (en) 2020-02-26
WO2018195397A2 (en) 2018-10-25
AU2018256459B2 (en) 2023-12-07
CN110831600A (zh) 2020-02-21
IL270025B1 (en) 2023-01-01
SG11201909710XA (en) 2019-11-28
US20200331917A1 (en) 2020-10-22
CL2019003015A1 (es) 2020-03-27
US10570138B2 (en) 2020-02-25
IL270025B2 (en) 2023-05-01
CO2019011584A2 (es) 2020-02-18
CN110831600B (zh) 2023-10-17
JP2020517734A (ja) 2020-06-18
US20230028336A1 (en) 2023-01-26
US11358969B2 (en) 2022-06-14
KR20190141722A (ko) 2019-12-24
US20180327411A1 (en) 2018-11-15
IL270025A (es) 2019-12-31
CA3059939A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF